Search Results

You are looking at 261 - 270 of 384 items for :

  • "Neutropenia" x
  • Refine by Access: All x
Clear All
Full access

Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Mustafa A. Arain, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Linda Farkas, Ignacio Garrido-Laguna, Jean L. Grem, Andrew Gunn, J. Randolph Hecht, Sarah Hoffe, Joleen Hubbard, Steven Hunt, Kimberly L. Johung, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Michael J. Overman, Aparna Parikh, Hitendra Patel, Katrina Pedersen, Leonard Saltz, Charles Schneider, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Kristina M. Gregory, and Lisa A. Gurski

of diarrhea, dehydration, and severe neutropenia. 164 , 165 Irinotecan is inactivated by the enzyme uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), which is also involved in converting substrates such as bilirubin into more soluble forms

Full access

Kidney Cancer

Robert J. Motzer, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Michael A. Carducci, Sam S. Chang, Toni K. Choueiri, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, David Josephson, Timothy M. Kuzel, Ellis G. Levine, Daniel W. Lin, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Thomas W. Ratliff, Bruce G. Redman, Cary N. Robertson, Charles J. Ryan, Joel Sheinfeld, Philippe E. Spiess, Jue Wang, and Richard B. Wilder

the IFN-α arm. Severe adverse events (grade 3–4 toxicities) were acceptable, with neutropenia (12%), thrombocytopenia (8%), hyperamylasemia (5%), diarrhea (5%), hand-foot syndrome (5%), and hypertension (8%) being noteworthy in the sunitinib arm, and

Full access

NCCN Biosimilars White Paper: Regulatory, Scientific, and Patient Safety Perspectives

Andrew D. Zelenetz, Islah Ahmed, Edward Louis Braud, James D. Cross, Nancy Davenport-Ennis, Barry D. Dickinson, Steven E. Goldberg, Scott Gottlieb, Philip E. Johnson, Gary H. Lyman, Richard Markus, Ursula A. Matulonis, Denise Reinke, Edward C. Li, Jessica DeMartino, Jonathan K. Larsen, and James M. Hoffman

B-cell lymphoma, and splenic marginal zone lymphoma). They are also vital in the treatment of cancer and chemotherapy-induced anemia and neutropenia according to the NCCN Supportive Care Guidelines. To view the most recent version of these guidelines

Full access

Adoption of Gene Expression Profiling for Breast Cancer in US Oncology Practice for Women Younger Than 65 Years

Suzanne C. O'Neill, Claudine Isaacs, Calvin Chao, Huei-Ting Tsai, Chunfu Liu, Bola F. Ekezue, Nandini Selvam, Larry G. Kessler, Marc D. Schwartz, Tania Lobo, and Arnold L. Potosky

. 38. Chia VM Page JH Rodriguez R . Chronic comorbid conditions associated with risk of febrile neutropenia in breast cancer patients treated with chemotherapy . Breast Cancer Res Treat 2013 ; 138 : 621 – 631 . 39. Hall PS McCabe C

Full access

Acute Lymphoblastic Leukemia, Version 2.2015

Joseph C. Alvarnas, Patrick A. Brown, Patricia Aoun, Karen Kuhn Ballen, Stefan K. Barta, Uma Borate, Michael W. Boyer, Patrick W. Burke, Ryan Cassaday, Januario E. Castro, Peter F. Coccia, Steven E. Coutre, Lloyd E. Damon, Daniel J. DeAngelo, Dan Douer, Olga Frankfurt, John P. Greer, Robert A. Johnson, Hagop M. Kantarjian, Rebecca B. Klisovic, Gary Kupfer, Mark Litzow, Arthur Liu, Arati V. Rao, Bijal Shah, Geoffrey L. Uy, Eunice S. Wang, Andrew D. Zelenetz, Kristina Gregory, and Courtney Smith

-related adverse events in the PACE trial included thrombocytopenia (37%), rash (34%), dry skin (32%), abdominal pain (22%), neutropenia (19%), and anemia (13%); pancreatitis was the most common serious event, reported in 5% of patients. 83 These studies

Full access

Myelodysplastic Syndromes

Peter L. Greenberg, Eyal Attar, John M. Bennett, Clara D. Bloomfield, Uma Borate, Carlos M. De Castro, H. Joachim Deeg, Olga Frankfurt, Karin Gaensler, Guillermo Garcia-Manero, Steven D. Gore, David Head, Rami Komrokji, Lori J. Maness, Michael Millenson, Margaret R. O’Donnell, Paul J. Shami, Brady L. Stein, Richard M. Stone, James E. Thompson, Peter Westervelt, Benton Wheeler, Dorothy A. Shead, and Maoko Naganuma

dysplasia (RCUD), which includes refractory anemia (RA; unilineage erythroid dysplasia), refractory neutropenia (RN; unilineage dysgranulopoiesis), and refractory thrombocytopenia (RT; unilineage dysmegakaryocytopoiesis). RN and RT were previously classified

Full access

Acute Myeloid Leukemia, Version 2.2013

Margaret R. O’Donnell, Martin S. Tallman, Camille N. Abboud, Jessica K. Altman, Frederick R. Appelbaum, Daniel A. Arber, Eyal Attar, Uma Borate, Steven E. Coutre, Lloyd E. Damon, Jeffrey Lancet, Lori J. Maness, Guido Marcucci, Michael G. Martin, Michael M. Millenson, Joseph O. Moore, Farhad Ravandi, Paul J. Shami, B. Douglas Smith, Richard M. Stone, Stephen A. Strickland, Eunice S. Wang, Kristina M. Gregory, and Maoko Naganuma

therapy (2 of which were caused by differentiation syndrome). One death in Arm A and 3 in Arm B occurred during consolidation. Grade 3 or 4 neutropenia and thrombocytopenia lasting more than 15 days were significantly more frequent in Arm B compared with

Full access

Optimal Management of Malignant Pleural Effusions (Results of CALGB 30102)

Todd L. Demmy, Lin Gu, Jack E. Burkhalter, Eric M. Toloza, Thomas A. D'Amico, Susan Sutherland, Xiaofei Wang, Laura Archer, Linda J. Veit, Leslie Kohman, and the Cancer and Leukemia Group B

. One severe (grade 3) SAE occurred in the TP group (dyspnea) compared with 6 in the TCD group Table 2 Frequencies of Clinical Outcomes (3 pain and 1 each of leukocytosis, wound infection, and neutropenia). QOL Analyses The maximum

Full access

Current Issues in Vaccines for Adult Patients With Hematologic Malignancies

Nicolas C. Issa and Lindsey R. Baden

recipients at risk for severe infections, which may be mitigated partly by revaccination. 1 – 5 Patients with hematologic malignancies in general are at high risk for severe infections because of a combination of factors, including neutropenia, T

Full access

Risk Factors for Early Death After Rituximab-Based Immunochemotherapy in Older Patients With Diffuse Large B-Cell Lymphoma

Adam J. Olszewski, Kalyan C. Mantripragada, and Jorge J. Castillo

%), red blood cell transfusions (47%), and arrhythmias (4%). Similarly, Delarue et al 4 found an 18% rate of febrile neutropenia and a 4% rate of cardiovascular severe adverse effects, with 13% of all fatalities ascribed to complications of R-CHOP. The